脂肪肉瘤的分子机制与靶向治疗的研究进展
摘要
对脂肪肉瘤发生、发展和预后的相关分子机制研究不仅有助于分型诊断和预后评估,也有助于为靶向治疗提供新的干预目标。现将脂肪肉瘤的分子机制与靶向治疗的研究进展综述如下。
出处
《江苏医药》
CAS
2015年第14期1685-1688,共4页
Jiangsu Medical Journal
参考文献22
-
1Erickson-Johnson MR,Seys AR,Roth CW,et al.Carboxypeptidase M:a biomarker for the discrimination of welldifferentiated liposarcoma from lipoma[J].Mod Pathol,2009,22(12):1541-1547.
-
2Mariani O,Brennetot C,Coindre JM,et al.JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas[J].Cancer Cell,2007,11(4):361-374.
-
3He M,Aisner S,Benevenia J,et al.Epigenetic alteration of p16INK4agene in dedifferentiation of liposarcoma[J].Pathol Res Pract,2009,205(6):386-394.
-
4Singer S,Socci ND,Ambrosini G,et al.Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well differentiated and dedifferentiated liposarcoma[J].Cancer Res,2007,67(14):6626-6636.
-
5Brill E,Gobble R,Angeles C,et al.ZIC1overexpression is oncogenic in liposarcoma[J].Cancer Res,2010,70(17):6891-6901.
-
6Barretina J,Taylor BS,Banerji S,et al.Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy[J].Nat Genet,2010,42(8):715-721.
-
7Ray-Coquard I,Blay JY,Italiano A,et al.Effect of the MDM2antagonist RG7112on the P53pathway in patients with MDM2-amplified,well-differentiated or dedifferentiated liposarcoma:an exploratory proof-of-mechanism study[J].Lancet Oncol,2012,13(11):1133-1140.
-
8Demetri GD,Fletcher CD,Mueller E,et al.Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma[J].Proc Natl Acad Sci USA,1999,96(7):3951-3956.
-
9Debrock G,Vanhentenrijk V,Sciot R,et al.A phase II trial with rosiglitazone in liposarcoma patients[J].Br J Cancer,2003,89(8):1409-1412.
-
10Pishvaian MJ,Cotarla I,Wagner AJ,et al.Final reporting of a phase I clinical trial of the oral PPAR-gamma agonist,CS-7017,in patients with advanced malignancies[J].J Clin Oncol,2010,28(15Suppl):2526.
-
1齐晓薇,冯一中,吴玉玉.甲状腺乳头状癌组织中p14^(ARF)、p16^(INK4a)、MDM2的表达变化及意义[J].山东医药,2010,50(34):47-48.
-
2顾岩,孙勤暖,付秀华,李国华,王立红,霍小东.突变型p53、MDM2、caspase-3在非小细胞肺癌的表达及意义[J].内蒙古医学院学报,2009,31(1):29-35. 被引量：4
-
3李娟,黎友伦,程序.Nucleostemin与MDM2在肺腺癌组织中的表达及意义[J].生命科学研究,2010,14(4):340-344. 被引量：2
-
4马莉,柴大敏,李红伟,冯振中,张琼,陶仪声.Pokemon和MDM2在食管鳞癌组织中的表达及其临床意义[J].中国组织化学与细胞化学杂志,2015,23(3A):265-269. 被引量：2
-
5杨胜,王艳.i（12P）在生殖细胞瘤中的意义[J].中华肿瘤防治杂志,1995,11(4):304-304.
-
6艾东方,马敬,杨秀芳,季珊珊,王雪燕.MDM2在部分皮肤良恶性疾病中的研究进展[J].中国医药导刊,2012,14(6):1018-1019.
-
7常英军,邹正辉,王金凯.慢性粒细胞白血病:从分子机制到靶向治疗[J].国外医学（输血及血液学分册）,2001,24(6):505-508.
-
8闻梅娟,冯一中.MDM2和p53在口腔黏膜鳞状细胞癌和口腔白斑中的表达[J].河北医学,2014,20(2):213-216. 被引量：7
-
9曹佩瑷,范伟,卢丽艳.Myc基因表达与大肠癌相关性的研究[J].山东医药,2004,44(23):14-15.
-
10黄震,赵亚娟.MCM2、Ki-67在甲状腺滤泡性肿瘤中的表达及其意义[J].浙江实用医学,2007,12(4):254-255. 被引量：5
